Press Releases

 Sign up for email alerts here

 

Date Title and Summary Additional Formats
Toggle Summary CORRECTING and REPLACING Genocea to Present at the 2015 BIO CEO & Investor Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- First paragraph, second sentence of release (dated February 2, 2015 ) has been changed to reflect the correct time of the presentation, which now reads: The presentation is scheduled for Monday, February 9, 2015 at 8:00 a.m. EST in New York, NY .
View HTML
Toggle Summary Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing
- Consistent efficacy across potential Phase 3 clinical trial endpoints - - Once-yearly or less frequent maintenance dosing expected - - Company to host conference call at 9 a.m. ET today - CAMBRIDGE, Mass. , March 31, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a
View HTML
Toggle Summary Genocea Added to Russell 3000® and Russell 2000® Indices
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it has been added to the Russell 3000® and Russell 2000® Indices as part of Russell
View HTML
Toggle Summary Genocea Added to Russell 3000® and Russell 2000® Indices
CAMBRIDGE, Mass. , June 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it has been added to the Russell 3000 ® and Russell 2000 ® Indices as part of the annual
View HTML
Toggle Summary Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of
View HTML
Toggle Summary Genocea Announces Immuno-Oncology Research Collaboration with Memorial Sloan Kettering Cancer Center
- Goal is to Utilize ATLAS TM to Discover Biologically Relevant Neoantigens for Vaccine Development - - Company to Discuss Collaboration and Oncology Strategy on Third Quarter 2015 Earnings Call at 9am ET Today - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Genocea Biosciences, Inc.
View HTML
Toggle Summary Genocea Announces New Research Identifying Potential Vaccine Candidates for Chlamydia View HTML
Toggle Summary Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial
- Trial meets statistical significance vs. placebo for multiple clinical endpoints through six months - - End of Phase 2 meeting with FDA expected in Q1 2017 - - Phase 3 launch expected in Q4 2017 - - GEN-003 has potential to be first new treatment for genital herpes infections in more than 20
View HTML
Toggle Summary Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003
- Sustained viral shedding rate reduction of 58 percent from baseline at best dose improves upon established attractive product profile - - Efficacy seen consistently across several potential Phase 3 clinical endpoints - - End of Phase 2 meeting with FDA expected in late 2016 - - Company to host
View HTML
Toggle Summary Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003
- Full Data in Oral Presentation at Major Infectious Disease Medical Meeting in October 2014 - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive
View HTML